Carvedilol Articles
Vasogen and IntelliPharmaCeutics agree to merge
17 August 2009
Flamel gets additional $4M GSK milestone
30 March 2009
GSK sees 2008 EPS fall; posts 2007 results
18 February 2008
US physician survey finds big differences in Rx patterns between cardiologists and PCPs
4 February 2008
3rd-qtr global pharmaceutical R&D pipeline report from Fitch
17 December 2007
GSK buys heart drug specialist for $1.65B
26 November 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
GSK's full-year 2006 turnover up 7%
12 February 2007
Strong data for GSK's Coreg seen at ASH
29 May 2006
FDA accepts GSK's Coreg CR NDA for review
20 March 2006
Daiichi Sankyo sees increase in 2005 income
20 February 2006
Better-than-expected 1st qtr for Daiichi
22 August 2005
GSK EPS rises 10% on 6% sales growth
8 August 2005
GlaxoSmithKline sees 10% EPS rise on 6% sales growth
1 August 2005
Daiichi FY2005 net income soars 39%
16 May 2005
Japan stock market week to March 28
4 April 2005
FDA warns GSK over misleading Coreg data
14 February 2005
Daiichi sees first-half revenues fall 2%
15 November 2004
Tokyo pharma stocks - week to October 4
11 October 2004
KrKa sees net profit rocket 65% for 1st half
20 September 2004
Daiichi Pharma
23 August 2004
GSK's 1st-qtr profit continues decline
10 May 2004
Tokyo pharma stocks - week to March 8
15 March 2004
Japan announces 4.2% average Rx price cut
15 March 2004
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
GSK drops Flamel augmentin deal
27 October 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
Positive HF data for Roche's Eucardic
8 September 2003
Positive results for GSK/Roche's Eucardic
7 July 2003
COMET backs Coreg over metoprolol in CHF
19 May 2003
GSK's Coreg gets post-MI mortality claim
7 April 2003
Stock Commentary - Week to Feb 17 - Europe
24 February 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
Beta blockers safe in heart failure
17 February 2003
GSK secures additional indication for Coreg from FDA panel
13 January 2003
Resovist recommended for approval in Japan
22 July 2002
Tokyo pharma stocks - week to July 8
15 July 2002
Eucardic gains additional indication
7 January 2002
Eucardic gains additional indication
18 December 2001
GSK's Coreg cleared for severe heart failure
2 November 2001
Stock Commentary - Tokyo
6 September 2001
Japan pharma stocks, week to Sept 3rd
5 September 2001
New guidance for CHF treatment aims at non-cardiologists
4 September 2001
Tokyo pharma stock market to May 7, 2001
8 May 2001
Roche launches Dilatrend in China
8 May 2001
First launch for SmithKline Beecham's argatroban in HIT
15 November 2000
SB sells Kytril, Famvir and Vectavir for $2.9bn
31 August 2000
SB/Roche's Coreg shows benefit in advanced heart failure
31 August 2000
Roche halts carvedilol trial in heart failure
23 March 2000
Merck's bisoprolol gets heart failure OK
9 December 1999
Roche revenues hit 20 billion Swiss francs
14 October 1999
SB sales increase 11% boosted by Avandia
21 July 1999
Currency impact lifts SmithKline Beecham
20 April 1999
Ranbaxy and Cipla in Indian marketing pact
26 February 1999
Roche recovers non-US carvedilol license
2 February 1999
Beta Blockers Show Further Value In Heart Failure
18 November 1998
Solid Third Quarter At SB Thanks To New Products
20 October 1998
Altana Expands Overseas Thanks To Pantoprazole
13 August 1998
Currency And Flu Factors Hold Back SB Results
22 July 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Roche To Copromote SB's Coreg In USA
7 May 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
Roche Sales Soar In 1st Quarter 1998
7 April 1998
Merck KGaA Halts Bisoprolol Trial
12 March 1998
Currency Hits SmithKline Beecham Sales And Profits
17 February 1998
Coreg Launched In The USA
19 June 1997
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
Roche/Corange Deal Comfirms Global Strategy
9 June 1997
FDA Clears SB's Carvedilol For CHF
9 June 1997
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
